

**Gattone, Robert**

---

**From:** Langhorst, Sue <slanghorst@wustl.edu>  
**Sent:** Friday, March 17, 2017 12:29 PM  
**To:** Gattone, Robert  
**Subject:** [External\_Sender] Corrected first page for February 14, 2017 notification report  
**Attachments:** Y-90 TS ME rept to NRC 2017 02 14-corr first page.pdf

Dear Mr. Gattone,

Please find attached a pen-and-ink correction for the first page of the February 14, 2017 report of §35.3045 event as per your request. The correction changes “3047(d)” in the first paragraph to “3045(d)”. Again, I apologize for the original typographical error.

Susan M. Langhorst  
Radiation Safety Officer  
Washington University in St. Louis

 **Washington University in St. Louis**

Environmental Health &amp; Safety

Radiation Safety Office

February 14, 2017

U.S. Nuclear Regulatory Commission  
Region III  
Nuclear Materials Licensing Section  
2443 Warrensville Road, Suite 210  
Lisle, Illinois 60532-4352

**Attn:** Regional Administrator**RE:** License No. 24-00167-11  
Docket No. 030-02271**Subject:** Report of §35.3045 event in accordance with "Yttrium-90 Microsphere Brachytherapy Sources and Devices TheraSphere® and SIR-Spheres® Licensing Guidance" (February 12, 2016, Revision 9)  
Event Report No. 52520

3045(d) *gmb*  
3/17/17

In accordance with §35.3047(d), this written report is being submitted following our January 31, 2017 telephone notification to the NRC Operations Center of a medical event that occurred on April 8, 2016.

**Licensee's name:** Washington University in St. Louis**Name of prescribing physician:** Perry W. Grigsby, M.D.**Brief description of the event:**

The patient was being treated for liver cancer. The patient was administered a first dose of Y-90 TheraSpheres on March 3, 2016. The authorized user (AU) for this written directive prescribed 5.22 GBq Y-90 TheraSpheres to deliver a 118 Gy dose to the right liver lobe, and 5.14 GBq was the delivered activity. The first administration of Y-90 TheraSpheres was done in accordance with the manufacturer's procedures without incident. The patient was administered a second dose of Y-90 TheraSpheres on April 8, 2016. The prescribing physician was the AU for the second written directive. He prescribed 4.15 GBq Y-90 TheraSpheres to deliver a 117 Gy dose to